Tag: Cancer: Prostate
FDA Approves Lynparza for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
Approval is for Lynparza with abiraterone and prednisone (or prednisolone)
Transient Benefit in Outcomes Seen With Androgen Suppression + RT for Prostate Cancer
Transient clinically meaningful decline noted in EPIC hormonal and sexual domains with total androgen suppression added to radiation
Transgender Women May Be Underdiagnosed With Prostate Cancer
Findings suggest link to more aggressive disease among estrogen users, but researchers say larger studies needed
Western Diet May Have Detrimental Effect on Prostate Cancer Risk
Stronger diet effect seen in Gleason grade group >6 and in International Society of Urological Pathology grade 3 + 4 + 5 tumors
Addition of Metastasis-Directed Therapy Increases PFS in Prostate Cancer
Addition of MDT, consisting of radiation therapy, to hormone therapy results in improved progression-free survival
Germline Genetic Testing Feasible for Advanced Prostate Cancer
High satisfaction reported for genetic testing model including education, follow-up with genetic counselor
Guideline Updated for Initial Management of Advanced Prostate Cancer
Triplet therapy should be offered to patients with de novo metastatic noncastrate prostate cancer with high-volume disease
Active Surveillance for Low-, Intermediate-Risk Prostate Cancer on the Rise
However, significant differences in use seen by race/ethnicity, education, and geography
Initiating Salvage RT When PSA >0.25 ng/mL Linked to All-Cause Mortality
Risk for all-cause mortality up for men receiving post-radical prostatectomy salvage radiation therapy at PSA level >0.25 ng/mL
Long-Term Waterborne-Ingested Nitrate Linked to Prostate Cancer Risk
Higher associations seen for those with lower intakes of fiber, fruit/vegetables, and vitamin C
